Latest news with #Pureprofile
Yahoo
11-08-2025
- Business
- Yahoo
High Growth Tech Stocks To Watch In Australia August 2025
The Australian market has been experiencing positive investor sentiment, with the ASX200 trading higher and sectors like Materials and Financials leading the charge, although Information Technology has faced some challenges alongside Utilities. In this environment, identifying high-growth tech stocks involves looking for companies that can navigate current market dynamics effectively while capitalizing on technological advancements and innovation. Top 10 High Growth Tech Companies In Australia Name Revenue Growth Earnings Growth Growth Rating Infomedia 6.81% 19.84% ★★★★☆☆ Pureprofile 13.56% 32.42% ★★★★☆☆ Pro Medicus 19.53% 21.56% ★★★★★☆ Echo IQ 49.20% 51.35% ★★★★★★ Life360 16.26% 40.50% ★★★★★☆ BlinkLab 51.57% 52.67% ★★★★★★ Kinatico 12.26% 51.47% ★★★★☆☆ Immutep 70.84% 42.55% ★★★★★☆ PYC Therapeutics 12.55% 24.30% ★★★★★☆ Xero 12.82% 23.77% ★★★★☆☆ Click here to see the full list of 21 stocks from our ASX High Growth Tech and AI Stocks screener. Below we spotlight a couple of our favorites from our exclusive screener. Data#3 Simply Wall St Growth Rating: ★★★★☆☆ Overview: Data#3 Limited is an IT solutions and services provider operating in Australia, Fiji, and the Pacific Islands with a market capitalization of A$1.17 billion. Operations: The company generates revenue primarily as a value-added IT reseller and solutions provider, with this segment contributing A$798.05 million. The business operates across Australia, Fiji, and the Pacific Islands. Data#3, a prominent name in Australian tech, is poised for robust growth with its revenue expected to surge by 20.1% annually, outpacing the national market's 5.6%. This growth trajectory is complemented by a forecasted return on equity of an impressive 60% in three years. The recent strategic board appointments of Diana Eilert and Laurence Baynham further bolster its leadership, blending deep industry experience and fresh perspectives crucial for navigating the evolving tech landscape. While its earnings growth projection of 10.1% trails slightly behind the broader Australian market's 10.9%, Data#3 maintains a competitive edge with quality earnings and positive free cash flow, indicating strong financial health and operational efficiency. Take a closer look at Data#3's potential here in our health report. Gain insights into Data#3's historical performance by reviewing our past performance report. Infomedia Simply Wall St Growth Rating: ★★★★☆☆ Overview: Infomedia Ltd is a technology company that develops and supplies electronic parts catalogues, service quoting software, and e-commerce solutions for the automotive industry worldwide, with a market capitalization of A$635.90 million. Operations: Infomedia generates revenue primarily through its publishing of periodicals, contributing A$142.41 million to its financial performance. The company's offerings focus on the automotive sector, providing essential digital tools that enhance parts cataloguing and service quoting processes for clients globally. Infomedia, an Australian tech firm, is set to grow its revenue by 6.8% annually, outpacing the broader market's 5.6%. This growth is supported by a robust R&D investment strategy that consistently enhances its software solutions, with recent figures showing a significant allocation of funds towards innovation. The company's earnings have surged by 19.8% per year, reflecting effective capital management and strategic initiatives like the recent acquisition agreement with TPG Growth Capital Asia Limited for AUD 650 million. This move could further solidify Infomedia's market position by expanding its service offerings and potentially increasing shareholder value through strategic synergies. Navigate through the intricacies of Infomedia with our comprehensive health report here. Evaluate Infomedia's historical performance by accessing our past performance report. PYC Therapeutics Simply Wall St Growth Rating: ★★★★★☆ Overview: PYC Therapeutics Limited is an Australian drug-development company focused on discovering and developing novel RNA therapeutics to treat genetic diseases, with a market cap of approximately A$734.91 million. Operations: PYC Therapeutics generates revenue primarily through the discovery and development of novel RNA therapeutics, amounting to approximately A$24.99 million. The company focuses on addressing genetic diseases using innovative RNA-based treatments. PYC Therapeutics, navigating through the competitive landscape of biotech, demonstrates a promising trajectory with an expected revenue growth rate of 12.6% annually, outpacing the Australian market average of 5.6%. Despite current unprofitability, forecasts indicate a shift towards profitability within three years, supported by an anticipated earnings growth of 24.3% per year. This growth is underpinned by strategic R&D investments aimed at pioneering treatments in genetic medicine, although it's crucial to note that shareholders have experienced dilution over the past year. As PYC moves towards its profitability milestones, its robust projected return on equity at 27.5% signals potential for substantial financial health improvement, aligning with its innovative thrust in a high-stakes industry. Click here to discover the nuances of PYC Therapeutics with our detailed analytical health report. Examine PYC Therapeutics' past performance report to understand how it has performed in the past. Make It Happen Navigate through the entire inventory of 21 ASX High Growth Tech and AI Stocks here. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors. Want To Explore Some Alternatives? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:DTL ASX:IFM and ASX:PYC. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Associated Press
25-05-2025
- Health
- Associated Press
New National Survey Reveals Tech Neck a Growing Public Health Concern
Get the heads up on tech neck! – National Spinal Health Week 26 May-1 June 'Women consistently reported higher neck pain rates for all devices and settings (home and workplace) and were significantly more affected by chronic pain, mental health impacts, and productivity loss.'— Dr Billy Chow SYDNEY, AUSTRALIA, May 25, 2025 / / -- Today, to launch Spinal Health Week, the Australian Chiropractors Association (ACA), released new data revealing 'tech neck' (Tension Neck Syndrome), is a significant public health concern due to overuse or misuse of technology with Australian women most susceptible to the debilitating condition. An independent survey by Pureprofile, 'The impact of tech neck and neck pain in Australia' revealed misuse of technology does more than cause neck pain; it's impacting every aspect of our daily lives. 'The survey revealed women are the primary sufferers of neck pain in every age bracket, except 51-60, with women aged 31-40 (73%) the most affected, reflecting a life-long, daily exposure to tech,' said ACA President Dr Billy Chow. 'Women consistently reported higher neck pain rates across all devices and settings (home and workplace), and were significantly more affected by chronic pain, mental health impacts, and productivity loss,' he said. The survey found female laptop users were 23% more likely than men to use non-ergonomic desks at work which was associated with a 16% higher incidence of neck pain than women using ergonomic workspaces. Overall, 64% of respondents reported neck pain with 70% of sufferers reporting that neck pain impeded their movement or day-to-day activities, which is higher than previous statistics of 1-in-5. 'Neck pain is a widespread, increasingly gendered issue in Australia, with 68% of women and 60% of men reporting symptoms, most linked to poor posture, extended screen time, and non-ergonomic device use. 'With only 36% of neck pain sufferers being aware their neck pain was linked to device use, to help prevent tech neck we must adjust our thinking on how we use technology, how often and the way we use it,' said Dr Chow. 'It was concerning that 38% of neck pain sufferers did not consult a healthcare practitioner; with 78% using over-the-counter pain relief and 47% relying on prescription medication to manage neck pain.' While medications may offer temporary relief from neck pain, academic studies show opioids do not benefit people with acute neck or back pain; comparatively, studies demonstrate commencing treatment for tech neck promptly is crucial in preventing further functional decline and progression to a chronic condition. Australians reported their mental health, and productivity was impacted with 24% experiencing higher irritability, 20% poorer concentration and 23% disrupted sleep with women 43% more effected by productivity loss than men. The survey revealed that proper posture, regular breaks, and correct ergonomics significantly reduced neck pain prevalence. Smartphone users who took regular breaks reported 33% less neck pain, while 85% of women device users who never took breaks experienced neck pain; compared to 61% of women who did. A worrying trend observed since COVID-19 is the surge in children and teens experiencing neck pain, making them vulnerable to spinal health issues and further health implications now and in the future. 'ACA Chiropractors reported a sharp rise in tech neck among young people with 34% reporting a 'significant increase (+25%)' and 27% a 'moderate increase (11-24%)' in teens. It's vital we educate kids on healthy device habits to prevent long-term neck-related health issues,' said Dr Chow. 'With technology a vital part of our lives, not only must we monitor the length of time we use devices but must be cognisant that overuse and how we use devices can negatively impact our spinal and mental health. 'The ACA recommends limiting recreational screentime to two hours per day, holding devices at eye level to prevent bending the neck forward, changing posture and taking regular breaks every ten minutes to look away from the device and move the neck from side-to-side,' Dr Chow said. Incorrect and non-ergonomic computer use is also a primary cause of tech neck. With 75.5% of Australians aged 16-to-64 using computers daily, incorrect and non-ergonomic use can cause musculoskeletal disorders (MSDs). 'MSDs, including tech neck, cost our economy over $55 billion annually through direct health costs, lost productivity and reduced quality of life, making the burden on Australians and our economy significant. 'Anytime you use a laptop or desktop computer it's essential to take regular breaks, move and stretch, and use correct ergonomics to help prevent tech neck,' he said Get the heads up on tech neck, visit Media Centre Alice Collins Insight Communications email us here Visit us on social media: LinkedIn Instagram Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Yahoo
18-05-2025
- Business
- Yahoo
Pureprofile Ltd's (ASX:PPL) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Most readers would already be aware that Pureprofile's (ASX:PPL) stock increased significantly by 22% over the past month. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance. Specifically, we decided to study Pureprofile's ROE in this article. ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. Put another way, it reveals the company's success at turning shareholder investments into profits. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. ROE can be calculated by using the formula: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Pureprofile is: 23% = AU$1.7m ÷ AU$7.1m (Based on the trailing twelve months to December 2024). The 'return' is the amount earned after tax over the last twelve months. That means that for every A$1 worth of shareholders' equity, the company generated A$0.23 in profit. Check out our latest analysis for Pureprofile We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features. To begin with, Pureprofile has a pretty high ROE which is interesting. Additionally, the company's ROE is higher compared to the industry average of 5.0% which is quite remarkable. So, the substantial 53% net income growth seen by Pureprofile over the past five years isn't overly surprising. We then compared Pureprofile's net income growth with the industry and we're pleased to see that the company's growth figure is higher when compared with the industry which has a growth rate of 24% in the same 5-year period. Earnings growth is a huge factor in stock valuation. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. This then helps them determine if the stock is placed for a bright or bleak future. Is Pureprofile fairly valued compared to other companies? These 3 valuation measures might help you decide. Pureprofile doesn't pay any regular dividends to its shareholders, meaning that the company has been reinvesting all of its profits into the business. This is likely what's driving the high earnings growth number discussed above. Overall, we are quite pleased with Pureprofile's performance. In particular, it's great to see that the company is investing heavily into its business and along with a high rate of return, that has resulted in a sizeable growth in its earnings. That being so, a study of the latest analyst forecasts show that the company is expected to see a slowdown in its future earnings growth. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
